BioCentury | Jul 9, 2020
Product Development

CSL testing coagulation factor blocker in COVID-19 patients; plus vaccine deals and plasma trials

...GS-5734) CSL Ltd. Coalition for Epidemic Preparedness Innovations (CEPI) Sichuan Clover Biopharmaceuticals Inc. GlaxoSmithKline plc Dynavax Technologies Corp. Medicago Inc. Emergent BioSolutions Inc. Mount Sinai Hospital U.S...
BioCentury | Jun 1, 2019
Product Development

Clinical trial and regulatory efficiency get help from ctDNA, RWE at ASCO19

...indications. One abstract from the company describes an analysis of 145,000 cancer patient records from Mount Sinai Hospital...
...Cambridge, U.K. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan IQVIA Holdings Inc. (NYSE:IQV), Durham, N.C. Mount Sinai Hospital...
...Staff Writer American Association for Cancer Research American Society of Clinical Oncology AstraZeneca plc Daiichi Sankyo Co. Ltd. IQVia Holdings Inc. Mount Sinai Hospital Pfizer...
BioCentury | Aug 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

...RNASEH2A and RNASEH2B could help treat triple-negative breast cancer (TNBC), cervical cancer and colorectal cancer Mount Sinai Hospital...
BioCentury | Jul 5, 2018
Preclinical News

New synthetic lethal interactions with PARP inhibition

...to find which synthetic lethal combinations are clinically relevant. In the Nature paper , a Mount Sinai Hospital...
...indication. Elizabeth S. Eaton Lynparza, olaparib (AZD2281, KU-0059436, MK-7339) talazoparib (MDV3800, bmn 673, bmn-673, lt-673) AstraZeneca plc Merck & Co. Inc. Mount Sinai Hospital Pfizer...
BioCentury | Apr 30, 2015
Distillery Techniques

Techniques: Protein interaction maps of targets for tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) combination therapies

...Other TECHNOLOGY: Computational models tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) Mount Sinai Hospital University of Manchester BC Staff...
BioCentury | Sep 22, 2014
Strategy

Weighing in on obesity

...said Jeffrey Mechanick, a clinical professor of medicine and endocrinology, diabetes and bone disease at Mount Sinai Hospital...
...Louis, Mo. The George Washington University , Washington, D.C. Institute for Integrated Healthcare, Greenville, S.C. Mount Sinai Hospital...
BioCentury | Aug 4, 2014
Emerging Company Profile

Encycle: Oral macrocycles

...therapeutics Disease focus: Autoimmune, cancer Clinical status: Preclinical Founded: 2012 by Andrei Yudin University collaborators: Mount Sinai Hospital...
BioCentury | May 29, 2014
Strategy

New York's biotech beginnings

...patient-derived tumors $100 million PPPs with undisclosed or unavailable funding details February 2013 Genisphere LLC Mount Sinai Hospital...
BioCentury | Apr 24, 2014
Targets & Mechanisms

Reversing (heart) failure in Friedreich's ataxia

...a control in the mouse models. Hajjar is a professor of medicine in cardiology at Mount Sinai Hospital...
...Médicale , Paris, France Institute of Genetics and Molecular and Cellular Biology , Illkirch, France Mount Sinai Hospital...
BioCentury | Apr 24, 2014
Targets & Mechanisms

Mired in miR-25

...Center at the Icahn School of Medicine and a professor of medicine in cardiology at Mount Sinai Hospital...
...Utrecht, the Netherlands Maastricht University , Maastricht, the Netherlands miRagen Therapeutics Inc. , Boulder, Colo. Mount Sinai Hospital...
Items per page:
1 - 10 of 45
BioCentury | Jul 9, 2020
Product Development

CSL testing coagulation factor blocker in COVID-19 patients; plus vaccine deals and plasma trials

...GS-5734) CSL Ltd. Coalition for Epidemic Preparedness Innovations (CEPI) Sichuan Clover Biopharmaceuticals Inc. GlaxoSmithKline plc Dynavax Technologies Corp. Medicago Inc. Emergent BioSolutions Inc. Mount Sinai Hospital U.S...
BioCentury | Jun 1, 2019
Product Development

Clinical trial and regulatory efficiency get help from ctDNA, RWE at ASCO19

...indications. One abstract from the company describes an analysis of 145,000 cancer patient records from Mount Sinai Hospital...
...Cambridge, U.K. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan IQVIA Holdings Inc. (NYSE:IQV), Durham, N.C. Mount Sinai Hospital...
...Staff Writer American Association for Cancer Research American Society of Clinical Oncology AstraZeneca plc Daiichi Sankyo Co. Ltd. IQVia Holdings Inc. Mount Sinai Hospital Pfizer...
BioCentury | Aug 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

...RNASEH2A and RNASEH2B could help treat triple-negative breast cancer (TNBC), cervical cancer and colorectal cancer Mount Sinai Hospital...
BioCentury | Jul 5, 2018
Preclinical News

New synthetic lethal interactions with PARP inhibition

...to find which synthetic lethal combinations are clinically relevant. In the Nature paper , a Mount Sinai Hospital...
...indication. Elizabeth S. Eaton Lynparza, olaparib (AZD2281, KU-0059436, MK-7339) talazoparib (MDV3800, bmn 673, bmn-673, lt-673) AstraZeneca plc Merck & Co. Inc. Mount Sinai Hospital Pfizer...
BioCentury | Apr 30, 2015
Distillery Techniques

Techniques: Protein interaction maps of targets for tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) combination therapies

...Other TECHNOLOGY: Computational models tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) Mount Sinai Hospital University of Manchester BC Staff...
BioCentury | Sep 22, 2014
Strategy

Weighing in on obesity

...said Jeffrey Mechanick, a clinical professor of medicine and endocrinology, diabetes and bone disease at Mount Sinai Hospital...
...Louis, Mo. The George Washington University , Washington, D.C. Institute for Integrated Healthcare, Greenville, S.C. Mount Sinai Hospital...
BioCentury | Aug 4, 2014
Emerging Company Profile

Encycle: Oral macrocycles

...therapeutics Disease focus: Autoimmune, cancer Clinical status: Preclinical Founded: 2012 by Andrei Yudin University collaborators: Mount Sinai Hospital...
BioCentury | May 29, 2014
Strategy

New York's biotech beginnings

...patient-derived tumors $100 million PPPs with undisclosed or unavailable funding details February 2013 Genisphere LLC Mount Sinai Hospital...
BioCentury | Apr 24, 2014
Targets & Mechanisms

Reversing (heart) failure in Friedreich's ataxia

...a control in the mouse models. Hajjar is a professor of medicine in cardiology at Mount Sinai Hospital...
...Médicale , Paris, France Institute of Genetics and Molecular and Cellular Biology , Illkirch, France Mount Sinai Hospital...
BioCentury | Apr 24, 2014
Targets & Mechanisms

Mired in miR-25

...Center at the Icahn School of Medicine and a professor of medicine in cardiology at Mount Sinai Hospital...
...Utrecht, the Netherlands Maastricht University , Maastricht, the Netherlands miRagen Therapeutics Inc. , Boulder, Colo. Mount Sinai Hospital...
Items per page:
1 - 10 of 45